Discovery of new antiviral agents through artificial intelligence: in vitro and in vivo results

arXiv:2611.22230 · q-bio.BM, cs.LG · Submitted 2026-11-17 · Read on arXiv

q-bio.BM, cs.LG

Submitted: 2026-11-17

Updated: 2026-11-17

Comments: Accepted manuscript. 13 pages, 5 figures; supplementary material included (supplementary text, Tables S1-S2, Figures S1-S5). Published in Antiviral Research 222 (2024) 105818

Journal ref: Antiviral Research 222 (2024) 105818

DOI: 10.1016/j.antiviral.2024.105818

License: http://creativecommons.org/licenses/by-nc-nd/4.0/

The gist: In this research, we employed a deep reinforcement learning (RL)-based molecule design platform to generate a diverse set of compounds targeting the neuraminidase (NA) of influenza A and B viruses.

Abstract

In this research, we employed a deep reinforcement learning (RL)-based molecule design platform to generate a diverse set of compounds targeting the neuraminidase (NA) of influenza A and B viruses. A total of 60291 compounds were generated, of which 86.5% displayed superior physicochemical properties compared to oseltamivir. After narrowing down the selection through computational filters, nine compounds with non-sialic acid-like structures were selected for in vitro experiments. We identified two compounds, DS-22-inf-009 and DS-22-inf-021 that effectively inhibited the NAs of both influenza A and B viruses (IAV and IBV), including H275Y mutant strains at low micromolar concentrations. Molecular dynamics simulations revealed a similar pattern of interaction with amino acid residues as oseltamivir. In cell-based assays, DS-22-inf-009 and DS-22-inf-021 inhibited IAV and IBV in a dose-dependent manner with EC50 values ranging from 0.29 uM to 2.31 uM. Furthermore, animal experiments showed that both DS-22-inf-009 and DS-22-inf-021 exerted antiviral activity in mice, conferring 65% and 85% protection from IAV (H1N1 pdm09), and 65% and 100% protection from IBV (Yamagata lineage), respectively. Thus, these findings demonstrate the potential of RL to generate compounds with promising antiviral properties.

Related papers